The Influence of Oxytocin and Prolactin During a First Episode of Psychosis: The Implication of Sex Differences, Clinical Features, and Cognitive Performance
Hidalgo-Figueroa, Maria ; Salazar, Alejandro ; Romero-Lopez-Alberca, Cristina ; MacDowell, Karina S. ; Garcia-Bueno, Borja ; Bioque, Miquel ; Bernardo, Miquel ; Parellada, Mara ; Gonzalez-Pinto, Ana ; Garcia Portilla, Maria Paz ; Lobo Satué, Antonio (Universidad de Zaragoza) ; Rodriguez-Jimenez, Roberto ; Berrocoso, Esther ; Leza, Juan C.
Resumen: Background Approximately 3% of the population suffers a first episode of psychosis (FEP), and a high percentage of these patients subsequently relapse. Because the clinical course following a FEP is hard to predict, it is of interest to identify cognitive and biological markers that will help improve the diagnosis, treatment, and outcome of such events and to define new therapeutic targets. Here we analyzed the plasma oxytocin and prolactin levels during an FEP, assessing their correlation with clinical and cognitive features. Methods The oxytocin and prolactin in plasma was measured in 120 FEP patients and 106 healthy controls, all of whom were subjected to a clinical and neuropsychological assessment. Most patients were under antipsychotics. Statistical analyses aimed to identify factors associated with the FEP and to search for associations between the variables. This study is preliminary and exploratory because the P-values were not corrected for multiple comparisons. Results FEP patients had less oxytocin, more prolactin, and a poor premorbid IQ, and they performed worse in sustained attention. Male patients with higher prolactin levels experienced more severe psychotic symptoms and required higher doses of antipsychotics. Low oxytocin was associated with poor sustained attention in women, whereas low oxytocin and high prolactin in men correlated with better performance in sustained attention. Conclusion Low oxytocin, high prolactin, and poor premorbid IQ and sustained attention are factors associated with an FEP, representing potential therapeutic targets in these patients. These biological factors and cognitive domains might play an important role during a FEP, which could help us to develop new strategies that improve the outcomes of this disorder and that should perhaps be gender specific.
Idioma: Inglés
DOI: 10.1093/ijnp/pyac023
Año: 2022
Publicado en: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY 25, 8 (2022), 666–677
ISSN: 1461-1457
Factor impacto JCR: 4.8 (2022)
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 65 / 278 = 0.234 (2022) - Q1 - T1
Categ. JCR: CLINICAL NEUROLOGY rank: 49 / 212 = 0.231 (2022) - Q1 - T1
Categ. JCR: PSYCHIATRY rank: 50 / 154 = 0.325 (2022) - Q2 - T1
Categ. JCR: NEUROSCIENCES rank: 80 / 272 = 0.294 (2022) - Q2 - T1
Factor impacto CITESCORE: 7.8 - Pharmacology, Toxicology and Pharmaceutics (Q1) - Medicine (Q1)
Factor impacto SCIMAGO: 1.406 - Pharmacology (Q1) - Psychiatry and Mental Health (Q1) - Pharmacology (medical) (Q1)
Financiación: info:eu-repo/grantAgreement/ES/ISCIII-FIS-FEDER/PI19-00766
Tipo y forma: Article (Published version)
Área (Departamento): Area Psiquiatría (Dpto. Medicina, Psiqu. y Derm.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes.
Exportado de SIDERAL (2024-03-18-14:43:16)
Visitas y descargas
Idioma: Inglés
DOI: 10.1093/ijnp/pyac023
Año: 2022
Publicado en: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY 25, 8 (2022), 666–677
ISSN: 1461-1457
Factor impacto JCR: 4.8 (2022)
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 65 / 278 = 0.234 (2022) - Q1 - T1
Categ. JCR: CLINICAL NEUROLOGY rank: 49 / 212 = 0.231 (2022) - Q1 - T1
Categ. JCR: PSYCHIATRY rank: 50 / 154 = 0.325 (2022) - Q2 - T1
Categ. JCR: NEUROSCIENCES rank: 80 / 272 = 0.294 (2022) - Q2 - T1
Factor impacto CITESCORE: 7.8 - Pharmacology, Toxicology and Pharmaceutics (Q1) - Medicine (Q1)
Factor impacto SCIMAGO: 1.406 - Pharmacology (Q1) - Psychiatry and Mental Health (Q1) - Pharmacology (medical) (Q1)
Financiación: info:eu-repo/grantAgreement/ES/ISCIII-FIS-FEDER/PI19-00766
Tipo y forma: Article (Published version)
Área (Departamento): Area Psiquiatría (Dpto. Medicina, Psiqu. y Derm.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. Exportado de SIDERAL (2024-03-18-14:43:16)
Permalink:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Articles
Record created 2022-07-15, last modified 2024-03-19